In this issue:
Long-term leukaemic progression in thrombocytopenic low-risk MDS treated with romiplostim or placebo
Ruxolitinib after and vs. interferon in RESPONSE studies
PSE for steroid-resistant chronic ITP
ITP and CV disease
Outcomes of previously untreated elderly AML patients
Melphalan 140 vs. 200 mg/m2 for autologous HSCT in myeloma
Brentuximab vedotin + nivolumab in relapsed/refractory Hodgkin’s lymphoma
Primary combination regimens and maintenance rituximab in Waldenström’s
Musculoskeletal ultrasound for intra-articular bleed detection
Please login below to download this issue (PDF)